An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis

Trial Profile

An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biocad
  • Most Recent Events

    • 07 Sep 2017 Phase of the trial changed from 2 to 2/3.Number of armas has cganged from 3 to4,hence number of planned patient has also changd from 165 to 399.
    • 07 Sep 2017 Planned number of patients changed from 165 to 399.
    • 07 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top